Haematology

Uzm. Dr. Ferda Can

Doctor and researcher Ankara Bilkent Şehir Hastanesi Ankara
COVID-19Leukemia, Myeloid, Chronic-PhaseLeukemia, Myeloid, AcuteSepsisAnemia, Iron-Deficiency
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • COVID-19 3 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Leukemia, Myeloid, Chronic-Phase 2 publications
  • Leukemia, Myeloid, Acute 2 publications
  • Sepsis 2 publications
  • Anemia, Iron-Deficiency 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyHaematologysaglik.gov.trFrom source
  • InstitutionAnkara Bilkent Şehir Hastanesisaglik.gov.trFrom source
  • Area of workCOVID-19Extracted from 3 publications · Model version —From source
  • Publications61 publicationsORCID, OpenAlex, Europe PMCFrom source
  • ORCID0000-0002-9899-1441ORCIDFrom source
  • Last synchronised5 November 2026 07:22https://ankarasehir.saglik.gov.tr/TR-331019/hematoloji-klinigi-doktorlarimiz.html#ferda-cansaglik.gov.tr

Scientific work

Publications on COVID-19

61 publications

  1. Prognostic Differences Between P190 and P210 BCR::ABL1 in Patients with Philadelphia-Positive B-cell Acute Lymphoblastic Leukemia

    Indian Journal of Hematology and Blood Transfusion, 2026

    DOI 10.1007/s12288-025-02095-8 PMID 41522562 Open-access full textSource: ORCID

  2. Olgular Eşliğinde Erişkin Hematoloji

    Akademisyen Kitabevi eBooks, 2026

    DOI 10.37609/akya.4308 Open-access full textSource: OpenAlex

  3. Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review

    Leukemia Research, 2026

    DOI 10.1016/j.leukres.2026.108239 PMID 42090741 Source: OpenAlex

  4. Real-world effectiveness and safety of fixed-duration frontline venetoclax–obinutuzumab for chronic lymphocytic leukemia: A nationwide multicenter retrospective cohort study

    Leukemia Research, 2026

    DOI 10.1016/j.leukres.2026.108342 PMID 42933070 Source: OpenAlex

  5. Clinical Characteristics, Treatment Approaches, and Survival Predictors in Adult Acute Myeloid Leukemia: Interim Results from the Turkish Society of Hematology AML Registry

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14207367 PMID 41156238 Open-access full textSource: OpenAlex

  6. AML-556: Personalized Therapy and Real-World Outcomes in Adult Acute Myeloid Leukemia: Lessons From a Nationwide Prospective Cohort in Turkey

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)01691-x Source: OpenAlex

  7. POSTER: AML-556 Personalized Therapy and Real-World Outcomes in Adult Acute Myeloid Leukemia: Lessons From a Nationwide Prospective Cohort in Turkey

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)00540-3 Source: OpenAlex

  8. Comprehensive analysis of FLT3-mutated patients with acute myeloid leukemia with updated 2022 European LeukemiaNet recommendations: insights from the Turkish AML registry project

    BMC cancer, 2025

    DOI 10.1186/s12885-025-14987-z PMID 41073967 1 citation (Europe PMC) Open-access full textSource: Europe PMC

  9. HL-1088: Primary Hodgkin Lymphoma of the Stomach

    Clinical Lymphoma Myeloma & Leukemia, 2025

    DOI 10.1016/s2152-2650(25)02212-8 Source: OpenAlex

  10. Türkiye Klinikleri

    AYBU AVESIS, 2025

    Source: OpenAlex

View all 61 publications